Welcome! This blog contains research & information on lifestyle, nutrition and health for those with MS, as well as continuing information on the understanding of the endothelium and heart-brain connection. This blog is informative only--all medical decisions should be discussed with your own physicians.

The posts are searchable---simply type in your topic of interest in the search box at the top left.

Almost all of MS research is initiated and funded by pharmaceutical companies. This maintains the EAE mouse model and the auto-immune paradigm of MS, and continues the 20 billion dollar a year MS treatment industry. But as we learn more about slowed blood flow, gray matter atrophy, and environmental links to MS progression and disability--all things the current drugs do not address--we're discovering more about how to help those with MS.

To learn how this journey began, read my first post from August, 2009. Be well! Joan

Showing posts with label BNAC. Show all posts
Showing posts with label BNAC. Show all posts

Saturday, October 11, 2014

"We have confirmed Dr. Zamboni's results 100%"

It was only five years ago, September 2009, that I attended the very first CCSVI conference in Bologna, Italy.  Dr. Dake and I were invited as guests of Dr. Zamboni---and I was able to sit in on all of the sessions.  I took copious notes, and posted them on the internet.  I re-post the opening event notes  today, as a reminder of what has transpired.  I went to this conference, excited to see the cooperation of neurologists and vascular specialists.  I believed the benefits my husband received from his treatment would excite and encourage medical professionals in all fields.  I was naive.

I believe we have been let down and abandoned by a neurological community, which is intent on maintaining research funding and ties to the pharmaceutical industry.  I do not say this lightly.  I say it with a heavy heart. 
My bolding of the notes below illustrates my point.

The ISNVD will continue, and there are new members, mostly imaging and vascular specialists.  They are intent on understanding how restricted venous flow affects brain health.  They are not giving up on this investigation, despite the best efforts of others to thwart the reseach.  The Australian Alfred Hospital trial and Brave Dreams trials are still continuing.
And we are all older, wiser and most certainly not going away.
stay well,
Joan
++++++++++++++++++++++++++++++++++++++++
Monday September 7, 2009
Bologna Italy
CCSVI PreCongress Meeting
6pm

Dr. Paolo Zamboni welcomes the gathered doctors and guests to the CCSVI Cenaculum Studiorum.
His topic is CCSVI, How to Move Forward-
He states that there are professionals gathered here from the studies of the blood’s path on the blood brain barrier side to the nervous system and that we all must share opinions and have exchanges. We need to dialogue and to learn from each other.

The origin of Dr. Zamboni’s work in Multiple Sclerosis began when he was a vascular surgeon in Sardinia, Italy. Sardinia is noted for its high level of epidemiology in MS in the general population. During 1987-1992, he noted a high prevalence in children with malformations of the jugular veins. His paper on this topic, “So-Called Primary Venous Aneurysms” was published in 1990. He noted AV fistula and a closed ring stenosis that could not be crossed by their blood in these children, external compression and this vascular anomaly appeared to be congenital. 20 years later, 90% of these children he studied have been diagnosed with MS.

In 2002, Dr. Zamboni noted that positive urine hemosiderin- a disease marker used to assess the severity of chronic venous disease- was administered to MS patients while they were in the midst of relapse. All of the MS patients tested positive. After he published a paper on this, he received an e-mail from Dr. FA Schelling- which referred him to Dr. Torben Fog’s paper- “Topography of Plaques in MS” The note from Dr. Schelling stated that perhaps Dr. Zamboni would now find what he was looking for...that the lesions of MS spread counter current from normal venous flow, and that there was where he should begin to study.

Dr. Zamboni then began to dedicate his work to develop a system of diagnosis of venous flow in the brain. He has found 100% correspondence with CCSVI and MS. He believes an international training program in Echo-Color doppler needs to be developed. and that there needs to be cooperation of neurologists and vascular surgeons. He mentioned endothelial disrupters such as smoking, cpn, EBV, and intracellular iron deposition as all being means of exacerbating this mechanism of disease. He spoke of his collaboration with neurologist Dr. Fabrizio Salvi of Bologna and the Jacobs Neurological Dept of SUNY Buffalo as being an example of such a collaboration.

Dr. Robert Zivadinov, Assistant professor of Neurology at Jacobs Neurological Institute at SUNY, Buffalo and Buffalo Neuroimaging and Analysis spoke next as to the Aim of the Meeting. He stated that we need to synthesize the current concepts about evaluation, pathogenesis and clinical relevance of CCSVI in MS. Individual variability in MS makes identifying the causative process very difficult.
He stated that the Journal of Vascular Surgery will soon be publishing the open label EVT intervention results of Zamboni, and that the current study at Jacobs, which will be completed in October ‘09 with the original 8 patients from America- has confirmed Dr. Zamboni’s results 100%. Dr. Zivadinov said that Jacobs is now recruiting and training new centers to test, diagnose and treat CCSVI in America.

He stated that he believes the next ten years will see 20,000 papers on CCSVI in vitro, vivo and animal studies. He reiterated that we need cooperation of various practices to find the solution. We need both the neurological and vascular perspective. He will be presenting at ECTRIMS after the Bologna conference.

Dr. Claude Franceschi- Director of the Paris Hospital Vascular lab spoke next on the Hemodynamic Factors of CCSVI.
The venous system is responsible for draining tissue, and the central parameter of drainage, transmural pressure, is changed when venous drainage is impaired. If TMP is too high, tissue suffers, edema and inflammation and vein dilation results.

Extra pressure on the nervous system comes from cerebral spinal fluid. Hydrostatic pressure is posture related- changing when the patient is supine or standing. The residual pressure- in which arterial blood surges into the venous system- is reduced in micro circulation. There is an increase in DR (downstream resistance) which is blocked by an obstacle. Obstacles can cause collateral veins to open as vicarious shunts and CSF will be excessive, causing edema and plaques. Cerebrospinal tissue is more sensitive to this. He believes the answer to CCSVI may lie in postural therapy, or a direct change in pressure via the Liberation technique or stenting.

Dr. Fabrizio Salvi- Head neurologist at the University of Bologna spoke of his clinical observations as a neurologist working with the CCSVI paradigm for three years. He told us that in 500 MS patients he has tested now, 100% have CCSVI. He stated the doppler is a wonderful tool of diagnosis and their needs to be training in the technique. He has a hypothesis as to why there are different varieties of screening in high risk subjects- because prognosis is related to the type of malformation. He wants to answer the question if the Liberation procedure is a disease modifying treatment in MS. He will give proof tomorrow that there is plasticity and remyelination in the CNS and the Liberation procedure have proven to activate remyelination in the CNS as shown by MRI.
“Yes!!!” stated Dr. Salvi...”no one is lost!!”

Dr. Patricia Coyle of Stony Brook University asks a question-
“How do we diagnose CCSVI?” 
The first answer comes from Dr. Zivadinov-
Doppler investigation is the beginning. If there is non-direction of flow in any body condition, or continual flow in the opposite direction- CCSVI is implicated. Transcranial doppler in the deep cerebral veins shows reflux. And then it is necessary to locate the stenosis. In MS, the jugular/Vertebral veins flow is consistently subverted. Dr. Zivadinov states that they had tested a 25 year old girl who had come into Jacobs as a control. A healthy girl, who presented with bilateral jugular occlusion. Months later, she had her first CIS attack of MS, and an MRI was done to show two lesions. She also has a familial history of MS. He reiterated that all of the doppler testing was blinded, yet it corraborated CCSVI in MS 100%.

Dr. Dake then stated that he had also tested a relative of a confirmed MS patient. A woman who had not been diagnosed with MS, but who presented at Stanford with jugular occlusion and a variety of neurological deficits, yet no MS diagnosis. She also showed lesion activity on an MRI, and he stented he occlusion the day before he flew to Bologna.

Dr. Zamboni makes the final statement to this question...he wants to articulate again that flow is more important than stenosis- especially as a preliminary diagnostic tool.
We are dismissed and all walk to a lovely formal dinner at the beautiful estate, Circolo della Caccia.

Joan
link to original post on Facebook September 7, 2009

How research has been manipulated:









Wednesday, March 27, 2013

BNAC research : A Tale of Two Studies


March 27, 2013 at 2:43pm

There have been two venoplasty studies undertaken by the University of Buffalo and recently released/publicized.  I thought it might be good to compare them, side by side.  Because the conclusions and results are worlds apart, and there needs to be an explanation.

Dr. Robert Zivadinov is the lead investigator in both studies.

PREMiSe Study Phase #1  Cine/CSF Study  
Published in the Journal of Vascular Radiology March 2013
No publicity  
Discussed at International Society for Neurovascular Disease Conference

PREMiSe Study Phase #2
Poster/Publicity at American Academy of Neurology  March 2013
Press conferences, videos, lots of news coverage all over the world.

Both are Venoplasty studies in mainly RRMS patients.  

PREMiSe study phase 1--Dr. Robert Galleotti, treating IR 
has worked with Dr. Zamboni for many years, has treated hundreds of CCSVI patients
an expert in venoplasty for CCSVI.  Venous drainage is improved >75%


"Improved venous parenchyma drainage"  Lower number of lesions on MRI for treated patients, less relapses.  
More studies are warranted!  PTA is good for the brain.


PREMiSe study phase 2-- Dr. Adnan Siddiqui, treating IR, relatively new to CCSVI venoplasty
Venous drainage is NOT improved to marker of >75%.  In fact, it is only improved to 50%!  (meaning treatment was a failure!!!)
 Headlines read, Liberation Therapy may make MS worse!
Nine patients treated, showed 19 new lesions on MRI.  PTA is bad.


 "more sizable changes in venous outflow [were] associated with increased disease activity primarily noted on MRI,"  Dr. Zivadinov and his colleagues concluded.


How are we to know what to believe? 
Is venoplasty helpful or harmful?  Is this about experience in the treating IR?  
Is this about how research is framed for the different audiences of vascular vs. neurological conferences?  

If phase 2 of PREMiSe did not reach a restoration of <75% venous flow, as it was supposed to....is this trial a failure?  

Because one study shows the venoplasty for CCSVI reduces lesions, relapses and improves CSF and venous drainage when flow is restored to <75%.

while the other study shows the exact opposite.
Which is the truth?

Does anyone want to answer this?
Joan

Wednesday, August 24, 2011

BNAC review: Venous stasis and EBV, viruses and bacteria



August 24, 2011 at 9:19pm

It is quite possible that venous stasis, or slowed cerebral drainage, could be responsible for the number of viruses (such as EBV and HHV) and bacteria (such as Cpn and Lyme) that have been associated with MS-by allowing these infectious agents to pass through the blood brain barrier.  Here is the Buffalo review on this topic:

The association between EBV infection and CCSVI has not yet been explored; however, it could be hypothesized that venous stasis in the superior saggital sinus due to extracranial outflow impairment could affect the drainage of bridging veins that pass through the subarachnoid space (near the meninges and EBV-infected B-cell follicles) and contribute to EBV activation. The venous stasis hypothesis in the SSS may contribute to understanding why so many different viruses and bacteria [3,111] have been linked to increased MS susceptibility risk over the last 50 years.

The blood brain barrier is supposed to keep viruses and bacteria out of the central nervous system.  Venous stasis, or slowed blood flow, would explain why so many infectious cells are passing into the brain and spine in MS.  It just makes sense!   More studies ahead.

Joan

Friday, August 12, 2011

From Dr. Zamboni on new published research


August 12, 2011 at 1:22pm

An important message from Dr. Zamboni regarding the newly published study placed online today.  This is the 2nd  CCSVI endovascular treatment study undertaken in Ferrara, Italy.  The patients were Italian and American, in cooperation with BNAC.   There were two groups, an immediate treatment group, and a delayed treatment group,  The MRI technicians were blinded as to who was in which group.  All patients were on disease modifying drugs before, during and after, for consistancy in treatment.   This is very important to understand.  Angioplasty for CCSVI reduced lesions, improved MS symtoms and reduced relapses, when compared to those in the delayed group on the drugs alone.  Here's the note from Dr. Zamboni-
_______________________________________________________

Here attached for you, from the site of the European Journal of Vascular Endovascular Surgery, the second treatment study.  This study is also known as MS-EVT treatment of American and Italian patients who have traveled from across the Atlantic to be treated.
http://www.ejves.com/article/S1078-5884%2811%2900201-2/abstract

The study design is unique in the history of medicine. The patients were operated on in Ferrara, but the results were audited in Buffalo. Patients were divided into two mixed groups of Italians and Americans. The first ITG  (immediate treatment group) was operated on immediately, while the second group DTG (delayed treatment group) was treated six months later, allowing us to compare the ITG with DTG. Finally, we compared patients in the second six months, when both groups were operated on.  Then, all patients were compared with their original state during the previous year, prior to PTA.

The study is small (we had no money to do more), however, is very strong, certainly stronger than that of 2009 JVS, as it eliminates many of the criticisms of the latter. Particularly--

1. There is a control group for comparison, in practice it as a randomized as possible for use in surgery
2. MRI measures are rigorous, high-standard 3-tesla, comparable and indisputable as completely blind
3. Patients were evaluated by neurologists and neuroradiologists of two centers
4. Statistical analysis was done by an independent statisticians and blinded.

What does it prove


1. Both groups after the PTA had a significant improvement in the MSFC score compared to previous year, with substantial maintenance of EDSS (no disease progression)
2. In the ITG during the first 6 months there were fewer relapses. The percentage has been on an annual basis of 0.16 against 0.66 of the DTG. In fact the DTG in the first six months received only drugs. After surgery, the DTG no longer had more relapses than the ITG, confirming the protective effect of PTA on relapses.
3. ITG  T2 lesion load decreased while the DTG increased. After the PTA in the DTG lesion load stabilized during the second six months.
4. Complications were zero, zero thrombosis
5. 27% restenosis
6. ITG had one patient- despite the PTA, who had a recurrence and worsening on the MRI, confirming that the MS-CCSVI can not be handled alone by only interventionist. This article suggests the causes of deterioration after PTA on which new studies are needed.

More results

1. Ahead Zivadinov and all 17 consecutive patients had venography confirmed CCSVI
2. the ITG had an effect more pronounced in brain volume reduction than that of the DTG, a likely anti-edema and anti-inflammatory effect of the PTA.

Key messages

* CCSVI is associated with MS --as the first treatment of the condition changes the clinical parameters of the second
* The modification of parameters in a blinded MRI is totally immune from the placebo effect, then measured the improvements are real
* The treatment is safe in safe hands and can be beneficial
* To say after these two pilot studies, positive treatment studies, epidemiological studies have to wait is not sustainable

Paolo Zamboni, MD
Director, Vascular Diseases Center
University of Ferrara